Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Desmopressin intranasal - CPX Pharmaceuticals/Acerus Pharmaceuticals

Next Previous
X
Search
Drug Profile

Desmopressin intranasal - CPX Pharmaceuticals/Acerus Pharmaceuticals

Alternative Names: AV002 - Avadel Pharmaceuticals; Desmopressin acetate; Intranasal desmopressin - Acerus Pharmaceuticals; Noctiva; NOCTIVA Nasal Spray; SER 120; SER-120 - CPX Pharmaceuticals/Acerus Pharmaceuticals

Latest Information Update: 14 Aug 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CPEX Pharmaceuticals; Serenity Pharmaceuticals Corporation
  • Developer Acerus Pharmaceuticals
  • Class Antidiuretics; Antihaemorrhagics; Hormones; Peptides; Urologics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Nocturia

Most Recent Events

  • 09 Aug 2022 Acerus Pharmaceuticals anticipates re-launch of Noctiva™ for Nocturia in USA, in the first quarter of 2023
  • 07 Mar 2022 Serenity Pharmaceuticals Corporation has been acquired and merged into Acerus Pharmaceuticals
  • 07 Feb 2019 Avadel Pharmaceuticals terminates its licence for Desmopressin intranasal in USA and Canada

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top